LANCL1 antisense RNA 1 (LANCL1-AS1)

LANCL1 antisense RNA 1 (LANCL1-AS1) is a **long non-coding RNA (lncRNA)** transcribed antisense to the LANCL1 gene, with primary localization in the cytoplasm. It regulates tumor biology in non-small-cell lung cancer (NSCLC) by functioning as a **competing endogenous RNA (ceRNA)**, binding to miR-3680-3p and thereby modulating the expression of GMFG, a gene involved in tumor progression. LANCL1-AS1 acts as a tumor suppressor, and its downregulation is associated with increased proliferation, migration, invasion, and angiogenesis of NSCLC cells. Moreover, higher LANCL1-AS1 expression is linked to better prognosis and increased sensitivity to therapies such as gefitinib. While it is identified as a disease biomarker and a potential candidate for therapeutic strategies (particularly RNA-based therapies), it is **not a classical therapeutic target** like a receptor, enzyme, or transporter[1][3][4][5][6]. **Note:** Although LANCL1-AS1 is not a protein-coding gene or a direct "target" in the traditional sense, it plays an important regulatory role in cancer biology and may be useful as a biomarker or for RNA-based therapeutic approaches.

Other names

LANCLOTLANCL1 opposite transcriptLANCL1-AS1

Not applicable for direct drug targeting (drugs do not bind lncRNAs), but overexpression alters cell drug sensitivity (e.g., increased gefitinib sensitivity via tumor suppression pathway regulation)[1]